Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis
Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis
复制标题
去铁胺治疗对类风湿性关节炎相关慢性贫血的影响
DOI：
10.1007/bf01816434
复制
发表时间：
2005
影响因子：
4
通讯作者：
I. Portioli
中科院分区：
文献类型：
--
作者：
C. Salvarani;R. Baricchi;D. Lasagni;L. Boiardi;R. Piccinini;C. Brunati;P. Macchioni;I. Portioli
objective.通过检测白细胞介素-6（IL-6）和促红细胞生成素（EPO）的产生，探讨去铁胺（DFO）对类风湿关节炎（RA）慢性病性贫血（CDA）的影响。5例RA合并CDA患者（I组）接受DFO治疗，500 mg/d，每周5天，连续10 h皮下输注，持续4周。停药后1个月，所有5名第I组患者（第II组）恢复DFO，按照先前的治疗方案增加至每日1 g。在两个研究期间，每周评价一次临床和实验室参数。采用放射免疫法测定血清EPO水平。采用酶联免疫吸附法检测IL-6。在第I组患者中未观察到血液学参数、IL-6或EPO水平的显著变化。DFO每日1 g治疗1周后，网织红细胞计数和EPO显著改善。血红蛋白和红细胞压积在每日1 g DFO治疗3周后显著升高。DFO停药后4周，EPO、网织红细胞计数、血红蛋白和红细胞压积恢复至基线水平。观察到疾病活动的临床参数显著改善，特别是在II组患者中。DFO改善RA患者的CDA。对红细胞生成的有益作用似乎与改善EPO对贫血的反应性有关。
Objective. To investigate the effects of desferrioxamine (DFO) infusion on chronic disease anemia (CDA) of rheumatoid arthritis (RA) by evaluating interleukin-6 (IL-6) and erythropoietin (EPO) production.Patients and methods. Five patients with RA and CDA (group I) were treated with DFO, 500 mg daily, through a continuous 10-h subcutaneous infusion 5 days a week for 4 weeks. One month after withdrawal, DFO was resumed in all five group I patients (group II) with an increase to 1 g daily following the previous treatment schedule. Clinical and laboratory parameters were evaluated weekly during the two study periods. Serum EPO was measured by radioimmunoassay. IL-6 was detected by the enzyme-linked immunoabsorbent assay method.Results. No significant variations in hematological parameters, IL-6 or EPO levels were observed in group I patients. After 1 week of DFO 1 g daily, reticulocyte counts and EPO improved significantly. Hemoglobin and hematocrit rose significantly after 3 weeks of 1 g daily DFO therapy. Four weeks after DFO withdrawal, EPO, reticulocyte counts, hemoglobin and hematocrit returned to baseline levels. A significant improvement in the clinical parameters of disease activity was observed, particularly in group II patients.Conclusion. DFO improves CDA in RA patients. The beneficial effects on erythropoiesis seem to be related to improved EPO responsiveness to the anemia.
影响因子：
20.3
作者：
Guang-lei Wang;G. Semenza
通讯作者：
Guang-lei Wang;G. Semenza